 Leverkusen, Germany, March 31, 2021 GLOBE NEWSWIRE -- Biofrontera AG NASDAQ: BFRA; Frankfurt Stock Exchange: B8F the Company, an international biopharmaceutical company, today announced the submission for approval of a new, significantly larger red-light source for photodynamic therapy PDT to be used in combination with Ameluz, the BF-RhodoLED XL, to the U.S. Food and Drug Administration FDA. 